APA (7th ed.) Citation

Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K., Azim, H., . . . Pivot, X. (2017). Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 82, 237. https://doi.org/10.1016/j.ejca.2017.05.010

Chicago Style (17th ed.) Citation

Gligorov, J., et al. "Safety and Tolerability of Subcutaneous Trastuzumab for the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer: SafeHer Phase III Study's Primary Analysis of 2573 Patients." European Journal of Cancer 82 (2017): 237. https://doi.org/10.1016/j.ejca.2017.05.010.

MLA (9th ed.) Citation

Gligorov, J., et al. "Safety and Tolerability of Subcutaneous Trastuzumab for the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer: SafeHer Phase III Study's Primary Analysis of 2573 Patients." European Journal of Cancer, vol. 82, 2017, p. 237, https://doi.org/10.1016/j.ejca.2017.05.010.